MAYO CLINIC LABORATORIES

Test Definition: ECULI

Eculizumab, Serum

Reporting Title: Eculizumab, S
Performing Location: Rochester

Ordering Guidance:

Therapeutic drug monitoring of eculizumab may be useful when providers are considering personalized treatment decisions, such as therapy discontinuation of extended dose intervals when patients are in remission states.

Specimen Requirements:

Patient Preparation: Suggest discontinuing natalizumab at least 4 weeks prior to testing for eculizumab quantitation in serum. Patient should consult the healthcare provider who prescribed this drug to determine if discontinuation is an option. If not, ok to proceed with testing while taking natalizumab**.**
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Draw blood immediately before next scheduled dose.
2. Immediately after specimen collection, place the tube on wet ice.
3. After specimen has clotted on wet ice, centrifuge at 4 degrees C and aliquot serum into plastic vial.
4. Freeze specimen within 30 minutes of centrifugation. Specimen must be placed on dry ice if not frozen immediately.

Forms:

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Renal Diagnostics Test Request (T830)
-Coagulation Test Request (T753)
-Therapeutics Test Request (T831)

Specimen Type	Temperature	Time	Special Container
Serum	Frozen (preferred)	30 days	
	Refrigerated	28 days	
	Ambient	4 days	

Result Codes:

Result ID	Reporting Name	Type	Unit	LOINC®
65676	Eculizumab, S	Numeric	mcg/mL	90240-3

LOINC® and CPT codes are provided by the performing laboratory.

Supplemental Report:

No

CPT Code Information:

80299

Reference Values:

Lower limit of quantitation =5.0 mcg/mL

>35 Therapeutic concentration for paroxysmal nocturnal hemoglobinuria (PNH)

>50 Therapeutic concentration for atypical hemolytic uremic syndrome (aHUS)